Online citations, reference lists, and bibliographies.
← Back to Search

Safety And Efficacy Of Lamivudine-zidovudine Combination Therapy In Zidovudine-experienced Patients. A Randomized Controlled Comparison With Zidovudine Monotherapy. Lamivudine European HIV Working Group.

S. Staszewski, C. Loveday, J. Picazo, P. Dellarnonica, P. Skinhøj, M. Johnson, S. Danner, P. Harrigan, A. Hill, L. Verity, H. McDade
Published 1996 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
OBJECTIVE To compare the safety and efficacy of 2 doses of lamivudine given in combination with zidovudine with continued zidovudine monotherapy. DESIGN Double-blind, randomized, multicenter, comparative trial of 223 patients treated for 24 weeks. SETTING Patients from 32 hospitals in Europe were enrolled throughout a 1-year period. PATIENTS Adult human immunodeficiency virus type 1 (HIV-1)-positive, zidovudine-experienced ( > or = 24 weeks prior zidovudine) patients with CD4+ cell counts between 0.10 and 0.40 x 10(9)/L (100-400 cells/microL). INTERVENTION Patients received either 200 mg of zidovudine every 8 hours, 150 mg of lamivudine every 12 hours plus zidovudine, or 300 mg of lamivudine every 12 hours plus zidovudine for 24 weeks. All patients were then allowed to receive zidovudine and open-label lamivudine combination therapy. Twelve patients withdrew because of adverse events during the 24-week treatment period. MAIN OUTCOME MEASURES Efficacy was measured by evaluating immunological and viral load changes, and safety was assessed by evaluating clinical manifestations and laboratory indexes of toxic effects. RESULTS Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued zidovudine monotherapy during the first 24 weeks as documented by changes in CD4+ cell counts (+0.04 vs +0.03 vs -0.02 x 10(9)/L, respectively; P < .001); log10 HIV-1 RNA as measured by the Roche assay (-0.96 vs -0.77 vs +0.07 copies/mL, respectively; P < .001) or log10 HIV-1 RNA measured by the quantitative nucleic acid sequence-based amplification assay (-0.59 vs -1.06 vs -0.02 copies/mL, respectively; P < .011); and immune-complex dissociated (ICD) p24 antigen (-74% vs -68% vs +27%, respectively; P < .001). There were no statistically significant differences in viral measurements, in CD4+ cell counts, or in safety profile between the groups receiving 2 doses of lamivudine in combination with zidovudine. The effects on CD4+ cell counts and ICD p24 antigen were sustained throughout 48 weeks for patients continuing combination therapy. Patients switching to combination therapy at week 24 showed improvement. CONCLUSION In zidovudine-experienced HIV-1-infected patients, combination treatment with lamivudine and zidovudine is well tolerated and provides greater and more sustained increases in CD4+ cell counts and decreases in viral load than continued zidovudine monotherapy.

This paper is referenced by
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation
O. Stirrup (2020)
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Pedro Cahn (2019)
Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
T. P. Dumitrescu (2019)
Oral Candida colonization in HIV-infected patients: Species and antifungal susceptibility in Tripoli/Libya
H Mohamed (2018)
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection
R. Quercia (2018)
Tissue Compartmentalization and Tropism of HIV-1: A Dissertation
Robin L. Brese (2016)
The timing of introduction of pharmaceutical innovations in seven European countries
R. Westerling (2014)
Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response
J. Vercauteren (2013)
Reversed Phase LC-UV Method Development and Validation for Simultaneous determination of three antiretrovirals: Lamivudine, Zidovudine, Nevirapine and Possible Degradants in a Fixed Dose Pharmaceutical Product
Anjali Joshi (2012)
Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection
J. Chancellor (2012)
The investigation of genotypic antiretroviral drug resistance in the context of the South African national antiretroviral roll-out programme
V. Zyl (2012)
Evaluation of steady‐state pharmacokinetic interactions between ritonavir‐boosted BILR 355, a non‐nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects
F. Huang (2012)
A Prospective Evaluation of the Cost Effectiveness of Adding Lamivudine to Zidovudine-Containing Antiretroviral Treatment Regimens in HIV Infection
L. Lacey (2012)
Intérêt du traitement antirétroviral précoce chez l’adulte infecté par le VIH en Afrique sub-Saharienne
Desmorys Raoul Moh (2012)
Lamivudine Reduces Healthcare Resource Use when Added to Zidovudine-Containing Regimens in Patients with HIV Infection
L. Lacey (2012)
Combination Nucleoside/Nucleotide Reverse Transcriptase Inhibitors for Treatment of HIV Infection
Maxwell O Akanbi (2012)
Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment
M. Koot (2012)
Increased Risk of Severe Infant Anemia After Exposure to Maternal HAART, Botswana
S. Dryden-Peterson (2011)
Clinical management of HIV-1 resistance.
R. Paredes (2010)
The development of combination therapies for HIV infection.
M. Delaney (2010)
Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure.
S. Stegmann (2010)
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.
C. Hoffmann (2009)
Running with scissors: using antiretroviral therapy without monitoring viral load.
D. Smith (2008)
Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model
A. Phillips (2008)
Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches.
A. Avolio (2008)
Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver.
V. Desai (2008)
Disease management--constructing optimal NRTI-based combinations: past, present, and future.
D. Dieterich (2006)
Treatment of chronic hepatitis B
S. Mohanty (2006)
Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future
D. Dieterich (2006)
Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses.
R. Schinazi (2006)
Zidovudine, Lamivudine, and Abacavir
M. Carten (2006)
Bacterial diarrhea in persons with HIV infection, United States, 1992-2002.
T. Sanchez (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar